Cepton Secures Industry’s Largest ADAS Lidar Series Production Win with Leading Detroit-Based Global Automotive OEM
13.7.2021 16:00:00 EEST | Business Wire | Press release
Lidar solutions provider Cepton Technologies, Inc. (“Cepton”) announced that it has secured an ADAS lidar series production award at a leading, Detroit-based global automotive OEM (“Detroit-based OEM”), which is the industry’s largest award to-date [1]. This represents a landmark milestone both for the lidar industry as well as for Silicon Valley-based Cepton, which celebrates its five-year anniversary this month.
The Detroit-based OEM is expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars. This marks the potential for an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.
Cepton secured this path-breaking, series production win in partnership with Koito Manufacturing Co., Ltd. (“Koito”), a leading automotive lighting Tier 1 supplier that is both a Cepton partner and investor. With this partnership, Cepton has provided a non-exclusive license to Koito to manufacture a version of Cepton’s MMT ®-based Vista®-X90 automotive grade lidar, using key components and technologies from Cepton. Substantial progress has been made in the Vista®-X90 product development over the past 18 months since the series production award.
The multiple OEM vehicle models already awarded as part of this series production program makes this win the largest in the industry to-date. The deployment of Cepton lidars in those vehicle models, as well as anticipated models to be added in the coming years at the Detroit-based OEM, is expected to significantly exceed that in any of the other publicly announced lidar series production programs. This is a testament to Cepton’s patented MMT® lidars, which utilize a rotation-free, mirrorless and frictionless technology that balances outstanding performance, high reliability and low cost, which are the three key factors integral to delivering mass-market ADAS lidar. Cepton’s MMT® lidars also feature a superior combination of compact size and low power consumption, which maximizes flexibility for vehicle integration, enabling various placement options such as in the fascia, in headlamps, on the roof and behind windshields. Cepton’s Vista®-X90 lidar consequently enables seamless and innovative vehicle-lidar integration.
“We are thrilled to work with an automotive OEM that is not just considered one of the global leaders in the industry but also a recognized pioneer and leader in ADAS and autonomous driving,” said Cepton CEO and co-founder, Dr. Jun Pei. “We are honored to have been chosen to help fulfill their long-term vision for vehicle safety and autonomy. We are also gratified to partner with Koito and leverage their manufacturing and quality leadership in this pathbreaking series production program, which I believe will set the standard for future ADAS lidar adoption.”
Dr. Pei added, “We founded Cepton in 2016 with an emphasis on ADAS and centered our lidar innovation around the goal of making lidar an essential automotive safety sensor in everyday passenger cars. We are now focused on delivering a safer and more enjoyable driving experience to consumers within the next few years.”
About Cepton
Cepton is one of the world’s leading providers of state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements herein are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect Cepton’s current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including (i) the success of our strategic relationships, including with our Tier 1 partners and OEM customers, none of which are exclusive; (ii) fluctuations in sales of Cepton’s major customers; (iii) current trends in the automotive markets. Cepton does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
[1] Largest known series production award by number of vehicle models awarded and based on publicly available information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005461/en/
Contact information
Cepton Media Relations: Faithy Li - media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom